Difference between revisions of "Sipuleucel-T (Provenge)"
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.dendreon.com/prescribing-information.pdf Sipuleucel-T (Provenge) package insert]</ref><ref>[http://hemonc....") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.dendreon.com/prescribing-information.pdf Sipuleucel-T (Provenge) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/sipuleucelt.pdf Sipuleucel-T (Provenge) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Autologous cellular immunotherapy, with each dose containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. Autologous peripheral blood mononuclear cells, which include antigen presenting cells (APCs), are obtained via leukapheresis. They are then activated in vitro with prostatic acid phosphatase (PAP), an antigen expressed in prostate cancer tissue, linked to [[Sargramostim (Leukine)|granulocyte-macrophage colony-stimulating factor (GM-CSF)]], and reinfused into the patient. The reinfused cells are then hypothesized to mediate immune reactions against prostate cancer cells.<ref name="insert">[http://www.dendreon.com/prescribing-information.pdf Sipuleucel-T (Provenge) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/sipuleucelt.pdf Sipuleucel-T (Provenge) package insert (locally hosted backup)]</ref><ref>[http://www.provenge.com/ Provenge manufacturer's website]</ref> |
| − | <br>Route: | + | <br>Route: IV |
| − | <br>Extravasation: | + | <br>Extravasation: no information |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.uptodate.com/contents/ | + | *[http://www.dendreon.com/prescribing-information.pdf#page=16 Sipuleucel-T (Provenge) package insert PDF pages 16-17]<ref name="insert"></ref> |
| + | *[http://www.uptodate.com/contents/sipuleucel-t-patient-drug-information Sipuleucel-T (Provenge) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sipuleucel-t-patient-drug-information Sipuleucel-T (Provenge) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 20:49, 24 February 2012
General information
Class/mechanism: Autologous cellular immunotherapy, with each dose containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. Autologous peripheral blood mononuclear cells, which include antigen presenting cells (APCs), are obtained via leukapheresis. They are then activated in vitro with prostatic acid phosphatase (PAP), an antigen expressed in prostate cancer tissue, linked to granulocyte-macrophage colony-stimulating factor (GM-CSF), and reinfused into the patient. The reinfused cells are then hypothesized to mediate immune reactions against prostate cancer cells.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Sipuleucel-T (Provenge) package insert PDF pages 16-17[1]
- Sipuleucel-T (Provenge) patient drug information (UpToDate)[4]